Pacira BioSciences, Inc. filed post-effective amendments to thirteen Form S-8 registration statements on November 17, 2026, deregistering all remaining unsold shares under those statements following the completion of its merger with Viatris Inc.

Key Highlights

  • Thirteen registration statements terminated: All post-effective amendments are numbered from Registration No. 333-175101 through Registration No. 333-297971, covering equity compensation and employee stock purchase plans.
  • Merger completed November 17, 2026: According to the filing, Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., merged with and into Pacira BioSciences, with Pacira surviving as a wholly owned subsidiary of Viatris.
  • Merger Agreement dated October 8, 2026: The filing identifies the Agreement and Plan of Merger as entered into among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc. on that date.
  • No shares remain registered: The filing states that "after giving effect to these Post-Effective Amendments, there will be no remaining Shares registered by the Company pursuant to the Registration Statements."
  • Common stock par value $0.001 per share: Shares deregistered were shares of common stock, par value $0.001 per share, of Pacira BioSciences, Inc., a Delaware corporation.
  • Signed by President Michael Rainerman: The post-effective amendments were executed on behalf of the registrant by Michael Rainerman, President, in Brisbane, California.

Pacira BioSciences Closes Out Equity Plan Registrations Following Viatris Merger

Pacira BioSciences, Inc. (NASDAQ:PCRX), a pharmaceutical company incorporated in Delaware and headquartered at 2000 Sierra Point Parkway, Suite 900, Brisbane, California, filed post-effective amendments to thirteen previously active Form S-8 registration statements. These statements had been used to register shares of Pacira common stock available under a series of employee equity compensation and stock purchase plans that the company maintained over more than a decade. The plans covered under the deregistration include the Pacira Pharmaceuticals, Inc. 2007 Stock Option/Stock Issuance Plan, the Amended and Restated 2011 Stock Incentive Plan, the Amended and Restated 2014 Employee Stock Purchase Plan, and the Amended and Restated 2014 Inducement Plan, among others.

According to the filing, the trigger for the deregistration was the closing of the merger on November 17, 2026, pursuant to the Agreement and Plan of Merger dated October 8, 2026. Under the terms of that agreement, Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., merged with and into Pacira BioSciences, with Pacira surviving as a wholly owned subsidiary of Viatris. The filing notes that "as a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings and sales pursuant to the Registration Statements." Individual registration statements covered share counts ranging from 175,000 shares to 4,000,000 shares, with original filing dates spanning from June 23, 2011 to August 4, 2026.

The company cited undertakings made in the original registration statements as the basis for filing these post-effective amendments. Those prior undertakings committed the registrant to remove from registration, by post-effective amendment, any shares that remained unsold at the termination of the offerings. The filing confirms that, following these amendments, no shares remain registered under any of the thirteen registration statements.

What Was Disclosed

Pacira BioSciences filed post-effective amendments on November 17, 2026, to deregister all unsold shares across thirteen S-8 registration statements. The deregistration followed the completion of its merger with Viatris Inc. and was signed by President Michael Rainerman.